Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine symbols : Fnctf save search
Rabies Vaccine Market to Reach $ 1903.17 million by 2032, exhibiting a CAGR of 4.7% from 2023 to 2032: Allied Market Research
Published: 2023-11-25 (Crawled : 08:20) - prnewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
ELAN | $13.41 -1.69% -0.45% 4.1M
|
Process Industries
| Email alert
Add to watchlist
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
ZTS | News | $151.94 -0.71% 2.38% 3.3M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
vaccine reach research market
Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
Published: 2023-03-15 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7448 -3.51% -3.64% 3.1M
|
Health Technology
|
| O: -1.54%
H: 1.96%
C: 0.0%
meeting vaccine cancer
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
Published: 2023-02-07 (Crawled : 09:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
meeting vaccine program mrna presentation cancer
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
Published: 2023-02-06 (Crawled : 13:20) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -7.26%
H: 5.82%
C: 5.82%
meeting vaccine program mrna presentation cancer
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
Published: 2022-12-09 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
covid-19 fda designation candidate vaccine influenza fast track designation
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Published: 2022-12-08 (Crawled : 16:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -0.76%
H: 0.0%
C: 0.0%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.12%
H: 3.36%
C: 3.19%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 0.37%
H: 5.31%
C: 5.26%
covid-19 fda children vaccine authorization
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Published: 2022-11-16 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.52%
H: 1.45%
C: 1.11%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -1.45%
H: 2.36%
C: 2.31%
covid-19 candidate vaccine study
Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials
Published: 2022-11-04 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.93%
H: 0.0%
C: 0.0%
trials disease alzheimer's vaccine molecular
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Published: 2022-11-04 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.93%
H: 0.0%
C: 0.0%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 1.93%
H: 0.15%
C: -0.53%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 7.6%
H: 0.33%
C: -1.27%
covid-19 vaccine response
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Published: 2022-10-12 (Crawled : 15:00) - globenewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.41%
H: 2.49%
C: -0.14%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 3.4%
H: 4.91%
C: 2.06%
covid-19 fda children vaccine authorization
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
Published: 2022-09-26 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.61%
H: 1.19%
C: 0.05%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -1.21%
H: 4.5%
C: 0.67%
fda children vaccine application authorization
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Published: 2022-08-31 (Crawled : 14:20) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.75%
H: 1.98%
C: 1.98%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.35%
H: 0.6%
C: -1.7%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 0.63%
H: 1.42%
C: -2.27%
covid-19 fda vaccine granted authorization
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Published: 2022-08-23 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -0.87%
H: 0.0%
C: 0.0%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.98%
H: 0.21%
C: -0.85%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 0.13%
H: 1.14%
C: -0.84%
covid-19 children vaccine
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Published: 2022-08-22 (Crawled : 15:20) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 1.54%
H: 1.57%
C: 1.57%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.12%
H: 0.38%
C: -0.63%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -0.79%
H: 2.56%
C: 1.06%
covid-19 fda vaccine application authorization
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Published: 2022-07-27 (Crawled : 11:00) - globenewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.69%
H: 0.61%
C: 0.02%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -2.28%
covid-19 candidate vaccine study
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Published: 2022-06-29 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 1.06%
H: 0.0%
C: 0.0%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 1.79%
H: 2.31%
C: 1.43%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -4.58%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 3.2%
H: 4.97%
C: 1.76%
covid-19 vaccine agreement
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Published: 2022-06-25 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
| Email alert
Add to watchlist
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
covid-19 vaccine response
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Published: 2022-06-17 (Crawled : 14:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -4.49%
H: 0.0%
C: 0.0%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -1.76%
H: 5.75%
C: 5.5%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
covid-19 fda children vaccine authorization emergency use authorization
PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer’s DNA Vaccine
Published: 2022-05-24 (Crawled : 18:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
vaccine dna trial alzheimer’s molecular alzheimer's
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Published: 2022-05-23 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: 0.0%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 2.55%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -0.85%
H: 0.06%
C: -1.91%
covid-19 children vaccine
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.